Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 17/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416303 | 1.00 | CTPS1 (0.38) | CTPS1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL22869169 | 0.79 | CTPS1 (0.40) | CTPS1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL22758463 | 0.78 | CYP3A4 (0.37) | CTPS1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL21392181 | 0.78 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL30725706 | 0.78 | CTPS1 (0.40) | CTPS1 | |
| SCHEMBL21392093 | 0.78 | CTPS1 (0.40) | CTPS1 | |
| SCHEMBL21392028 | 0.77 | CYP2C19 (0.36) | CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL30518355 | 0.74 | CTPS1 (0.69) | CTPS1 | |
| SCHEMBL21391998 | 0.73 | CTPS1 (0.42) | CTPS1CYP17A1 | |
| SCHEMBL30415285 | 0.73 | CTPS1 (0.42) | CTPS1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CYP3A4 13/4885CYP2C9 15/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CYP3A4 13/4885CYP2C9 15/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | CTPS1 2704/4885CYP3A4 19/4885CYP2C9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.